Quent Long Short Global Small Cap Fund LP Makes New Investment in Merck & Co., Inc. $MRK

Quent Long Short Global Small Cap Fund LP bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,157 shares of the company’s stock, valued at approximately $859,000.

A number of other hedge funds have also made changes to their positions in the company. Chemung Canal Trust Co. increased its holdings in shares of Merck & Co., Inc. by 21.1% in the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock valued at $6,407,000 after purchasing an additional 13,285 shares during the last quarter. First Pacific Financial increased its holdings in shares of Merck & Co., Inc. by 14.7% in the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock valued at $3,991,000 after purchasing an additional 6,082 shares during the last quarter. Diversified Trust Co increased its holdings in shares of Merck & Co., Inc. by 9.6% in the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock valued at $17,444,000 after purchasing an additional 18,187 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 48.9% in the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after purchasing an additional 32,114 shares during the last quarter. Finally, Coldstream Capital Management Inc. increased its holdings in shares of Merck & Co., Inc. by 12.7% in the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock valued at $10,364,000 after purchasing an additional 13,940 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the sale, the executive vice president directly owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares of the company’s stock, valued at $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is currently owned by company insiders.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $114.68 on Friday. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The stock has a market cap of $283.25 billion, a PE ratio of 15.75, a P/E/G ratio of 2.27 and a beta of 0.26. The firm has a 50-day simple moving average of $118.80 and a two-hundred day simple moving average of $106.58. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same period last year, the business earned $1.72 earnings per share. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 4.93 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were given a dividend of $0.85 per share. The ex-dividend date was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted Priority Review for two supplemental BLA filings for KEYTRUDA in combination regimens for muscle‑invasive bladder cancer — this could expand a high‑value label for KEYTRUDA if approved, supporting future revenue. Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer
• Positive Sentiment: Merck announced a multi‑year partnership with Google Cloud (up to $1B) to deploy agentic AI across R&D, manufacturing and commercial functions — a strategic investment that could boost long‑term productivity, R&D efficiency and digital transformation. Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
• Positive Sentiment: FDA approved IDVYNSO, a once‑daily two‑drug, non‑INSTI, tenofovir‑free HIV regimen — a new approved product can contribute incremental sales and diversify Merck’s commercial portfolio. Merck Weighs New HIV Approval Against Mixed Oncology Trial Results
• Neutral Sentiment: Reports say Merck and other drugmakers are eyeing a deal for Inhibrx’s experimental cancer drug tied to KEYTRUDA — strategic M&A/licensing interest is a potential longer‑term positive but remains speculative and valuation‑dependent. Exclusive: Merck, rivals eye deal in Inhibrx experimental cancer drug tied to Keytruda, sources say
• Neutral Sentiment: Market research notes expansion in the polycythemia vera field and lists Merck’s bomedemstat as one of several emerging entrants — a potential long‑term opportunity but competitive and years from wide commercial impact. Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036
• Negative Sentiment: Merck and partner Eisai reported a late‑stage Keytruda‑based triplet in first‑line advanced renal cell carcinoma failed to meet primary endpoints — this clinical setback has already pressured the stock and raises near‑term uncertainty around that program and investor confidence in certain oncology readouts. MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
• Negative Sentiment: Analysts expect Merck to report a year‑over‑year earnings decline and note Merck lacks the key factors typically associated with an earnings beat — weaker near‑term EPS guidance/expectations can cap upside and prompt short‑term selling. Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

Analysts Set New Price Targets

MRK has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a report on Friday, February 13th. Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a research report on Thursday, January 8th. JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. UBS Group raised their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $128.47.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.